Understanding lateral flow tests in a post-pandemic world
10 Oct 2024
The COVID-19 pandemic has transformed the landscape of diagnostic testing, emphasizing the need for rapid, accurate, and accessible point-of-care solutions. Known for their simplicity and effectiveness, lateral flow tests use antibodies to detect specific antigens that indicate a certain disease or condition. Explore how the tests involve complex components and raw materials, with Merck providing technical and regulatory expertise in membrane choice and antibody development, ensuring consumer confidence in rapid test results.
About the company
Merck
The Life Science business of Merck KGaA, Darmstadt, Germany, which operates as MilliporeSigma in the U.S. and Canada, has some 22,000 employees and 59 manufacturing sites worldwide, with a portfolio of more than 300,000 products focused on scientific discovery, biomanufacturing and testing services.
